Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis

Thomas Graier; Wolfgang Weger; Paul-Gunther Sator; Wolfgang Salmhofer; Barbara Gruber; Constanze Jonak; Claudia Kölli; Martina Schütz-Bergmayr; Igor Vujic; Gudrun Ratzinger; Nina Häring; Clemens Painsi; Knut Prillinger; Alexander Mlynek; Hans Skvara; Hannes Trattner; Adrian Tanew; Roland Lichem; Christina Ellersdorfer; Franz Legat; Alexandra Gruber-Wackernagel; Angelika Hofer; Erich Schmiedberger; Wolfram Hoetzenecker; Robert Müllegger; Werner Saxinger; Franz Quehenberger; Peter Wolf

doi:10.1016/j.jdin.2020.10.012

Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis

Thomas Graier, Wolfgang Weger, Paul-Gunther Sator, Wolfgang Salmhofer, Barbara Gruber, Constanze Jonak, Claudia Kölli, Martina Schütz-Bergmayr, Igor Vujic, Gudrun Ratzinger, Nina Häring, Clemens Painsi, Knut Prillinger, Alexander Mlynek, Hans Skvara, Hannes Trattner, Adrian Tanew, Roland Lichem, Christina Ellersdorfer, Franz LegatAlexandra Gruber-Wackernagel, Angelika Hofer, Erich Schmiedberger, Wolfram Hoetzenecker, Robert Müllegger, Werner Saxinger, Franz Quehenberger, Peter Wolf

Division of Dermatology and Venereology (University Hospital St. Pölten)

Research output: Journal article (peer-reviewed) › Journal article

16 Citations (Scopus)

Abstract

BACKGROUND: Little is known about the effectiveness and drug survival associated with apremilast under real-world conditions.

OBJECTIVE: To investigate the influence of patient and disease characteristics on drug survival associated with apremilast and to elucidate clinical effectiveness with regard to the psoriasis area and severity index (PASI) reduction.

METHODS: This was an observational, retrospective, multicenter analysis from the Austrian Psoriasis Registry.

RESULTS: Data from 367 patients were eligible for analysis. The 12-month drug survival rate associated with apremilast (ie, the proportion of patients on the drug) was 57.3% and decreased significantly in patients younger than 40 years (relative hazard ratio = 1.49, P = .007918). Sex; concomitant arthritis; previous biologic therapy; obesity; and palmoplantar, scalp, nail, and intertriginous involvement did not significantly affect drug survival. At 12 months, the response rates in patients receiving apremilast per protocol with a PASI of 50, 75, 90, and 100 were 80.0%, 56.4%, 38.2%, and 22.7%, respectively.

LIMITATIONS: Inclusion of a substantial number of patients with no record of absolute PASI at study entry and lack of PASI reduction follow-up data of 103 patients (28.1%) after starting apremilast treatment.

CONCLUSION: Apremilast is a robust antipsoriatic drug for which the drug survival is not strongly influenced by most patient- or disease-related factors except age. Drug survival is significantly shorter in patients younger than 40 years.

Original language	English
Pages (from-to)	62-75
Number of pages	14
Journal	JAAD International
Volume	2
DOIs	https://doi.org/10.1016/j.jdin.2020.10.012
Publication status	Published - Mar 2021

Access to Document

10.1016/j.jdin.2020.10.012

Cite this

Graier, T., Weger, W., Sator, P.-G., Salmhofer, W., Gruber, B., Jonak, C., Kölli, C., Schütz-Bergmayr, M., Vujic, I., Ratzinger, G., Häring, N., Painsi, C., Prillinger, K., Mlynek, A., Skvara, H., Trattner, H., Tanew, A., Lichem, R., Ellersdorfer, C., ... Wolf, P. (2021). Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis. JAAD International, 2, 62-75. https://doi.org/10.1016/j.jdin.2020.10.012

@article{39e8b1358883486286c9d33f71ce8a87,

title = "Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis",

abstract = "BACKGROUND: Little is known about the effectiveness and drug survival associated with apremilast under real-world conditions.OBJECTIVE: To investigate the influence of patient and disease characteristics on drug survival associated with apremilast and to elucidate clinical effectiveness with regard to the psoriasis area and severity index (PASI) reduction.METHODS: This was an observational, retrospective, multicenter analysis from the Austrian Psoriasis Registry.RESULTS: Data from 367 patients were eligible for analysis. The 12-month drug survival rate associated with apremilast (ie, the proportion of patients on the drug) was 57.3% and decreased significantly in patients younger than 40 years (relative hazard ratio = 1.49, P = .007918). Sex; concomitant arthritis; previous biologic therapy; obesity; and palmoplantar, scalp, nail, and intertriginous involvement did not significantly affect drug survival. At 12 months, the response rates in patients receiving apremilast per protocol with a PASI of 50, 75, 90, and 100 were 80.0%, 56.4%, 38.2%, and 22.7%, respectively.LIMITATIONS: Inclusion of a substantial number of patients with no record of absolute PASI at study entry and lack of PASI reduction follow-up data of 103 patients (28.1%) after starting apremilast treatment.CONCLUSION: Apremilast is a robust antipsoriatic drug for which the drug survival is not strongly influenced by most patient- or disease-related factors except age. Drug survival is significantly shorter in patients younger than 40 years.",

author = "Thomas Graier and Wolfgang Weger and Paul-Gunther Sator and Wolfgang Salmhofer and Barbara Gruber and Constanze Jonak and Claudia K{\"o}lli and Martina Sch{\"u}tz-Bergmayr and Igor Vujic and Gudrun Ratzinger and Nina H{\"a}ring and Clemens Painsi and Knut Prillinger and Alexander Mlynek and Hans Skvara and Hannes Trattner and Adrian Tanew and Roland Lichem and Christina Ellersdorfer and Franz Legat and Alexandra Gruber-Wackernagel and Angelika Hofer and Erich Schmiedberger and Wolfram Hoetzenecker and Robert M{\"u}llegger and Werner Saxinger and Franz Quehenberger and Peter Wolf",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2021",

month = mar,

doi = "10.1016/j.jdin.2020.10.012",

language = "English",

volume = "2",

pages = "62--75",

journal = "JAAD International",

issn = "2666-3287",

publisher = "Elsevier B.V.",

}

Graier, T, Weger, W, Sator, P-G, Salmhofer, W, Gruber, B, Jonak, C, Kölli, C, Schütz-Bergmayr, M, Vujic, I, Ratzinger, G, Häring, N, Painsi, C, Prillinger, K, Mlynek, A, Skvara, H, Trattner, H, Tanew, A, Lichem, R, Ellersdorfer, C, Legat, F, Gruber-Wackernagel, A, Hofer, A, Schmiedberger, E, Hoetzenecker, W, Müllegger, R, Saxinger, W, Quehenberger, F & Wolf, P 2021, 'Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis', JAAD International, vol. 2, pp. 62-75. https://doi.org/10.1016/j.jdin.2020.10.012

TY - JOUR

T1 - Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast

T2 - A registry analysis

AU - Graier, Thomas

AU - Weger, Wolfgang

AU - Sator, Paul-Gunther

AU - Salmhofer, Wolfgang

AU - Gruber, Barbara

AU - Jonak, Constanze

AU - Kölli, Claudia

AU - Schütz-Bergmayr, Martina

AU - Vujic, Igor

AU - Ratzinger, Gudrun

AU - Häring, Nina

AU - Painsi, Clemens

AU - Prillinger, Knut

AU - Mlynek, Alexander

AU - Skvara, Hans

AU - Trattner, Hannes

AU - Tanew, Adrian

AU - Lichem, Roland

AU - Ellersdorfer, Christina

AU - Legat, Franz

AU - Gruber-Wackernagel, Alexandra

AU - Hofer, Angelika

AU - Schmiedberger, Erich

AU - Hoetzenecker, Wolfram

AU - Müllegger, Robert

AU - Saxinger, Werner

AU - Quehenberger, Franz

AU - Wolf, Peter

PY - 2021/3

Y1 - 2021/3

N2 - BACKGROUND: Little is known about the effectiveness and drug survival associated with apremilast under real-world conditions.OBJECTIVE: To investigate the influence of patient and disease characteristics on drug survival associated with apremilast and to elucidate clinical effectiveness with regard to the psoriasis area and severity index (PASI) reduction.METHODS: This was an observational, retrospective, multicenter analysis from the Austrian Psoriasis Registry.RESULTS: Data from 367 patients were eligible for analysis. The 12-month drug survival rate associated with apremilast (ie, the proportion of patients on the drug) was 57.3% and decreased significantly in patients younger than 40 years (relative hazard ratio = 1.49, P = .007918). Sex; concomitant arthritis; previous biologic therapy; obesity; and palmoplantar, scalp, nail, and intertriginous involvement did not significantly affect drug survival. At 12 months, the response rates in patients receiving apremilast per protocol with a PASI of 50, 75, 90, and 100 were 80.0%, 56.4%, 38.2%, and 22.7%, respectively.LIMITATIONS: Inclusion of a substantial number of patients with no record of absolute PASI at study entry and lack of PASI reduction follow-up data of 103 patients (28.1%) after starting apremilast treatment.CONCLUSION: Apremilast is a robust antipsoriatic drug for which the drug survival is not strongly influenced by most patient- or disease-related factors except age. Drug survival is significantly shorter in patients younger than 40 years.

AB - BACKGROUND: Little is known about the effectiveness and drug survival associated with apremilast under real-world conditions.OBJECTIVE: To investigate the influence of patient and disease characteristics on drug survival associated with apremilast and to elucidate clinical effectiveness with regard to the psoriasis area and severity index (PASI) reduction.METHODS: This was an observational, retrospective, multicenter analysis from the Austrian Psoriasis Registry.RESULTS: Data from 367 patients were eligible for analysis. The 12-month drug survival rate associated with apremilast (ie, the proportion of patients on the drug) was 57.3% and decreased significantly in patients younger than 40 years (relative hazard ratio = 1.49, P = .007918). Sex; concomitant arthritis; previous biologic therapy; obesity; and palmoplantar, scalp, nail, and intertriginous involvement did not significantly affect drug survival. At 12 months, the response rates in patients receiving apremilast per protocol with a PASI of 50, 75, 90, and 100 were 80.0%, 56.4%, 38.2%, and 22.7%, respectively.LIMITATIONS: Inclusion of a substantial number of patients with no record of absolute PASI at study entry and lack of PASI reduction follow-up data of 103 patients (28.1%) after starting apremilast treatment.CONCLUSION: Apremilast is a robust antipsoriatic drug for which the drug survival is not strongly influenced by most patient- or disease-related factors except age. Drug survival is significantly shorter in patients younger than 40 years.

UR - http://www.scopus.com/inward/record.url?scp=85125772236&partnerID=8YFLogxK

U2 - 10.1016/j.jdin.2020.10.012

DO - 10.1016/j.jdin.2020.10.012

M3 - Journal article

C2 - 34409355

SN - 2666-3287

VL - 2

SP - 62

EP - 75

JO - JAAD International

JF - JAAD International

ER -

Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this